This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nihart, M. A. Search for Related Content Social Bookmarking                         What's this?

Atypical Antipsychotics and the Pharmacology of Olanzapine

Turning Point Center in San Francisco, California; 146 Hilton Ln., Pacifica, CA 94044.

Atypical antipsychotics present exciting opportunities to improve the quality of life for many individuals who are experiencing the debilitating impact of schizophrenia, a syndrome with complex symptom presentations and unclear cause. In the past the antipsychotic efficacy was thought to correlate with the degree of dopamine blockade; this hypothesis has several limitations. Atypical antipsychotics hold promise for reduced side effects and improved efficacy in treating negative symptoms, possibly through the interactions of neurotransmitters such as serotonin and dopamine. Similar to clozapine, olanzapine (Zyprexa) has a bigh affinityfor a number of subtypes of dopamine receptors and other neurotransmitters. The interrelationship of its actions at multiple receptor sites may account for its improved efficacy in treating negative symptoms and its unique side effect profile.

Journal of the American Psychiatric Nurses Association, Vol. 3, No. 1, S2-S7 (1997)
DOI: 10.1177/107839039700300109


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?